Please Wait.....
Report
NA Laboratory-Developed Tests (LDTs) Market - Industry Trends and Forecast to 2030
Market Report I 2023-06-01 I 275 Pages I Data Bridge Market Research
The North America Laboratory-Developed Tests (LDTs) Market is expected to reach USD 17,680.85 Million by 2030 from USD 6,901.04 Million in 2022, growing at a CAGR of 12.5% during the forecast period of 2023 to 2030.
Market Segmentation
North America Laboratory-Developed Tests (LDTs) Market, By Test Type (Clinical Chemistry and Immunology, Critical Care, Hematology, Molecular Diagnostics, Microbiology, and Other Test), Product Type (Consumables, Analyzers and Instruments, and Accessories), Sample Type (Blood, Urine, Tissue, Cerebrospinal Fluid (CSF), and Others), Therapeutic Area (Infections, Genetic Disorders, Oncology/Cancer, Autoimmune Disease, Urology, Gynecology, and Others), Gender (Male, and Female), Age Group (Geriatrics, Adult, and Pediatric), End Users (Hospital-Based Labs, Stand-Alone Labs, Diagnostic Chains, Academic Institutes, Clinical Research Organizations, Specialty Diagnostic Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, Third Party Distributors, and Others), Country (U.S., Canada, Mexico) - Industry Trends and Forecast to 2030
Overview of North America Laboratory-Developed Tests (LDTs) Market Dynamics
Drivers
- Increasing demand for personalized medicines
- Advancements in molecular diagnostics
Restraint
- Stringent quality control and standardization for LDTs
Opportunity
- Increasing demand for precision medicine and targeted therapy
Market Players
Some of the major market players operating in the North America Laboratory-Developed Tests (LDTs) market are:
- F. Hoffmann-La Roche Ltd
- bioMerieux, Inc.
- Sysmex Corporation
- Biomerica, Inc.
- Bio-Rad Laboratories, Inc.
- Abbott
- Siemens Medical Solutions USA, Inc.
- Quest Diagnostics Incorporated
- QIAGEN
- Eurofins Scientific
- Biodesix.
- Hologic, Inc.
- Guardant Health
- OPKO Health, Inc.
- BD
- Beckman Coulter, Inc.
- NeoGenomics Laboratories.
- Seegene Inc.
- Ambry Genetics
- BGI
- 23andMe, Inc.
- Admera Health
- Agendia
TABLE OF CONTENTS
1 INTRODUCTION 65
1.1 OBJECTIVES OF THE STUDY 65
1.2 MARKET DEFINITION 65
1.3 OVERVIEW OF THE NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET 65
1.4 CURRENCY AND PRICING 67
1.5 LIMITATIONS 67
1.6 MARKETS COVERED 67
2 MARKET SEGMENTATION 72
2.1 MARKETS COVERED 72
2.2 GEOGRAPHICAL SCOPE 73
2.3 YEARS CONSIDERED FOR THE STUDY 74
2.4 DBMR TRIPOD DATA VALIDATION MODEL 75
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 78
2.6 MULTIVARIATE MODELLING 79
2.7 TEST TYPE SEGMENT LIFELINE CURVE 79
2.8 MARKET END USER COVERAGE GRID 80
2.9 DBMR MARKET POSITION GRID 81
2.10 VENDOR SHARE ANALYSIS 82
2.11 SECONDARY SOURCES 83
2.12 ASSUMPTIONS 83
3 EXECUTIVE SUMMARY 84
4 PREMIUM INSIGHTS 87
4.1 PESTEL ANALYSIS 88
4.2 PORTER'S FIVE FORCES MODEL 89
5 INDUSTRY INSIGHTS 90
6 NUMBER OF LABS 92
6.1 NUMBER OF LABS IN MIDDLE EASTERN COUNTRIES 92
6.2 NUMBER OF LABS IN EUROPE 92
7 REGULATIONS OF THE NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET 94
7.1 U.S. 94
8 MARKET OVERVIEW 95
8.1 DRIVERS 97
8.1.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 97
8.1.2 ADVANCEMENTS IN MOLECULAR DIAGNOSTICS 97
8.1.3 GROWING PREVALENCE OF CHRONIC DISEASES 97
8.1.4 INCREASING AWARENESS AND ACCEPTANCE TOWARDS THE ASSISTANCES OF LDTS 98
8.2 RESTRAINTS 98
8.2.1 STRINGENT QUALITY CONTROL AND STANDARDIZATION FOR LDTS 98
8.2.2 STRICT REGULATORY GUIDELINES REGARDING LDTS 99
8.3 OPPORTUNITIES 99
8.3.1 INCREASING DEMAND FOR PRECISION MEDICINE AND TARGETED THERAPY 99
8.3.2 ENHANCED HEALTHCARE SUBSTRUCTURE 100
8.4 CHALLENGES 100
8.4.1 DEPRIVED DATA INTERPRETATION AND INTEGRATION 100
8.4.2 COMPLEX LABORATORY PROCESSES 101
9 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE 102
9.1 OVERVIEW 103
9.2 CLINICAL CHEMISTRY AND IMMUNOLOGY 106
9.2.1 GLUCOSE 107
9.2.1.1 GLUCOSE CHALLENGE TEST 107
9.2.1.2 ORAL GLUCOSE TOLERANCE TEST (OGTT) 107
9.2.2 PROTHROMBIN 108
9.2.3 METABOLIC PANEL 108
9.2.3.1 BASIC 108
9.2.3.2 COMPREHENSIVE 108
9.2.4 LIPID PANEL 108
9.2.5 LIVER PANEL 108
9.2.5.1 ALP TEST (ALKALINE PHOSPHATE) 109
9.2.5.2 ALT TEST (ALKALINE TRANSMINASE) 109
9.2.5.3 AST TEST (ASPARTATE AMINOTRANSFERASE) 109
9.2.5.4 GAMMA-GLUTAMYL TRANSFERASE (GGT) TEST 109
9.2.6 THYROID STIMULATING HORMONE 109
9.2.7 URINALYSIS 109
9.2.7.1 RED BLOOD CELL URINE TEST 110
9.2.7.2 GLUCOSE URINE TEST 110
9.2.7.3 PROTEIN URINE TEST 110
9.2.7.4 URINE PH LEVEL 110
9.2.7.5 KETONES URINE TEST 110
9.2.7.6 BILIBURIN URINE TEST 110
9.2.7.7 URINE SPECIFIC GRAVITY TEST 111
9.2.8 OTHERS 111
9.3 CRITICAL CARE 111
9.3.1 CARBOXYHAEMOGLOBIN TEST 112
9.3.2 PH TEST 112
9.3.3 POTASSIUM TEST 112
9.3.4 SODIUM TEST 112
9.3.5 METHEMOGLOBIN TEST 112
9.3.6 LACTATE TEST 112
9.3.7 OTHERS 113
9.4 HAEMATOLOGY 113
9.4.1 COMPLETE BLOOD COUNT (CBC) 114
9.4.1.1 WHITE BLOOD CELL COUNT (WBC) 114
9.4.1.2 RED BLOOD CELL COUNT (RBC) 114
9.4.2 PLATELET COUNT 114
9.4.3 BLOOD PROTEIN TESTING 115
9.4.4 OTHERS 115
9.5 MOLECULAR DIAGNOSTIC 115
9.5.1 SAMPLE TYPE 116
9.5.1.1 BLOOD 116
9.5.1.2 URINE 116
9.5.1.3 TISSUE 116
9.5.1.4 CEREBROSPINAL FLUID (CSF) 116
9.5.1.5 OTHERS 116
9.5.2 THERAPEUTIC AREA 116
9.5.2.1 INFECTIONS 117
9.5.2.2 GENETIC DISORDERS 117
9.5.2.3 ONCOLOGY/CANCER 117
9.5.2.4 AUTOIMMUNE DISEASE 117
9.5.2.5 UROLOGY 117
9.5.2.6 GYNECOLOGY 117
9.5.2.7 OTHERS 117
9.5.3 TECHNOLOGY 118
9.5.3.1 POLYMERASE CHAIN REACTION (PCR) 118
9.5.3.2 NEXT-GENERATION SEQUENCING (NGS) 118
9.5.3.3 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 118
9.5.3.4 SANGER SEQUENCING 118
9.5.3.5 MICROARRAYS 118
9.5.3.6 MASS SPECTROMETRY 119
9.5.3.7 ISOTHERMAL AMPLIFICATION 119
9.5.4 END USER 119
9.5.4.1 HOSPITAL-BASED LABS 119
9.5.4.2 STAND-ALONE LABS 119
9.5.4.3 DIAGNOSTIC CHAINS 119
9.5.4.4 ACADEMIC INSTITUTES 120
9.5.4.5 CLINICAL RESEARCH ORGANIZATIONS 120
9.5.4.6 SPECIALTY DIAGNOSTIC CENTERS 120
9.5.4.7 OTHERS 120
9.6 MICROBIOLOGY 120
9.6.1 MICROSCOPY 121
9.6.2 CULTURE 121
9.6.3 ANTIMICROBIAL SUSCEPTIBILITY TEST 121
9.6.4 OTHERS 121
9.7 OTHER TEST 122
9.7.1 DRUGS OF ABUSE TESTING 123
9.7.2 HEPATITIS 123
9.7.3 HUMAN IMMUNODEFICIENCY VIRUSES (HIV) 123
9.7.4 MALARIA 123
9.7.5 TUBERCULOSIS 123
9.7.6 HUMAN PAPILLOMAVIRUS (HPV) 123
9.7.7 OTHERS 124
10 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE 125
10.1 OVERVIEW 126
10.2 CONSUMABLES 129
10.2.1 PANELS 129
10.2.2 REAGENT AND KITS 130
10.2.3 OTHERS 130
10.3 ANALYZERS AND INSTRUMENTS 130
10.3.1 FULLY-AUTOMATED INSTRUMENTS 131
10.3.2 SEMI-AUTOMATED INSTRUMENTS 131
10.3.3 OTHERS 131
10.4 ACCESSORIES 131
11 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE 133
11.1 OVERVIEW 134
11.2 BLOOD 137
11.3 URINE 137
11.4 TISSUE 138
11.5 CEREBROSPINAL FLUID (CSF) 138
11.6 OTHERS 139
12 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA 141
12.1 OVERVIEW 142
12.2 INFECTIONS 145
12.2.1 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 146
12.2.2 CLOSTRIDIUM DIFFICILE 146
12.2.3 VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE) 146
12.2.4 CARBAPENEM-RESISTANT BACTERIA 146
12.2.5 FLU 146
12.2.6 RESPIRATORY SYNCYTIAL VIRUS (RSV) 147
12.2.7 CANDIDA 147
12.2.8 TUBERCULOSIS AND DRUG-RESISTANT TBA 147
12.2.9 MENINGITIS 147
12.2.10 GASTROINTESTINAL PANEL TESTING 147
12.2.11 CHLAMYDIA 147
12.2.12 GONORRHEA 147
12.2.13 HIV 147
12.2.14 HEPATITIS B 147
12.2.15 HEPATITIS C 147
12.2.16 OTHER INFECTIOUS DISEASES 147
12.3 GENETIC DISORDERS 148
12.3.1 NEW BORN SCREENING 148
12.3.2 PREDICTIVE AND PRESYMPTOMATIC TESTING 149
12.3.3 OTHER GENETIC TESTING 149
12.4 ONCOLOGY/CANCER 149
12.4.1 BREAST CANCER 150
12.4.2 PROSTATE CANCER 150
12.4.3 COLORECTAL CANCER 150
12.4.4 CERVICAL CANCER 150
12.4.5 KIDNEY CANCER 150
12.4.6 LIVER CANCER 150
12.4.7 BLOOD CANCER 150
12.4.8 LUNG CANCER 151
12.4.9 OTHER CANCER 151
12.5 AUTOIMMUNE DISEASE 151
12.6 UROLOGY 151
12.7 GYNECOLOGY 152
12.8 OTHERS 153
13 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER 154
13.1 OVERVIEW 155
13.2 MALE 158
13.3 FEMALE 158
14 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP 160
14.1 OVERVIEW 161
14.2 GERIATRICS 164
14.3 ADULT 164
14.4 PEDIATRICS 165
15 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USER 166
15.1 OVERVIEW 167
15.2 HOSPITAL-BASED LABS 170
15.3 STAND -ALONE LABS 170
15.4 DIAGNOSTIC CHAINS 171
15.5 ACADEMIC INSTITUTES 172
15.6 CLINICAL RESEARCH ORGANISTAION 172
15.7 SPECIALTY DIAGNOSTIC 173
15.8 OTHERS 174
16 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL 175
16.1 OVERVIEW 176
16.2 DIRECT TENDER 179
16.3 RETAIL SALES 179
16.4 THIRD PARTY DISTRIBUTORS 180
16.5 OTHERS 181
17 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION 182
17.1 NORTH AMERICA 183
17.1.1 U.S. 198
17.1.2 CANADA 207
17.1.3 MEXICO 216
18 NORTH AMERICA LABORATORY-DEVELOPED TESTS (LDTS) MARKET, COMPANY LANDSCAPE 225
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 225
19 COMPANY PROFILES 226
19.1 F. HOFFMANN-LA ROCHE LTD. 226
19.1.1 COMPANY SNAPSHOT 226
19.1.2 REVENUE ANALYSIS 226
19.1.3 COMPANY SHARE ANALYSIS 227
19.1.4 PRODUCT PORTFOLIO 227
19.1.5 RECENT DEVELOPMENT 227
19.2 BIOMERIEUX 228
19.2.1 COMPANY SNAPSHOT 228
19.2.2 REVENUE ANALYSIS 228
19.2.3 COMPANY SHARE ANALYSIS 229
19.2.4 PRODUCT PORTFOLIO 229
19.2.5 RECENT DEVELOPMENTS 229
19.3 SYSMEX CORPORATION 230
19.3.1 COMPANY SNAPSHOT 230
19.3.2 REVENUE ANALYSIS 230
19.3.3 COMPANY SHARE ANALYSIS 231
19.3.4 PRODUCT PORTFOLIO 231
19.3.5 RECENT DEVELOPMENT 231
19.4 BIOMERICA. 232
19.4.1 COMPANY SNAPSHOT 232
19.4.2 REVENUE ANALYSIS 232
19.4.3 COMPANY SHARE ANALYSIS 233
19.4.4 PRODUCT PORTFOLIO 233
19.4.5 RECENT DEVELOPMENT 233
19.5 BIO-RAD LABORATORIES, INC 234
19.5.1 COMPANY SNAPSHOT 234
19.5.2 REVENUE ANALYSIS 234
19.5.3 COMPANY SHARE ANALYSIS 235
19.5.4 PRODUCT PORTFOLIO 235
19.5.5 RECENT DEVELOPMENT 235
19.6 23ANDME, INC. 236
19.6.1 COMPANY SNAPSHOT 236
19.6.2 REVENUE ANALYSIS 236
19.6.3 PRODUCT PORTFOLIO 237
19.6.4 RECENT DEVELOPMENTS 237
19.7 ABBOTT 238
19.7.1 COMPANY SNAPSHOT 238
19.7.2 REVENUE ANALYSIS 238
19.7.3 PRODUCT PORTFOLIO 239
19.7.4 RECENT DEVELOPMENT 239
19.8 ADMERA HEALTH 240
19.8.1 COMPANY SNAPSHOT 240
19.8.2 PRODUCT PORTFOLIO 240
19.8.3 RECENT DEVELOPMENT 240
19.9 AGENDIA. 241
19.9.1 COMPANY SNAPSHOT 241
19.9.2 PRODUCT PORTFOLIO 241
19.9.3 RECENT DEVELOPMENT 241
19.10 AMBRY GENETICS 242
19.10.1 COMPANY SNAPSHOT 242
19.10.2 PRODUCT PORTFOLIO 242
19.10.3 RECENT DEVELOPMENT 243
19.11 BD 244
19.11.1 COMPANY SNAPSHOT 244
19.11.2 REVENUE ANALYSIS 244
19.11.3 PRODUCT PORTFOLIO 245
19.11.4 RECENT DEVELOPMENTS 245
19.12 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER) 246
19.12.1 COMPANY SNAPSHOT 246
19.12.2 REVENUE ANALYSIS 246
19.12.3 PRODUCT PORTFOLIO 247
19.12.4 RECENT DEVELOPMENTS 247
19.13 BGI. 248
19.13.1 COMPANY SNAPSHOT 248
19.13.2 PRODUCT PORTFOLIO 248
19.13.3 RECENT DEVELOPMENT 249
19.14 BIODESIX. 250
19.14.1 COMPANY SNAPSHOT 250
19.14.2 REVENUE ANALYSIS 250
19.14.3 PRODUCT PORTFOLIO 251
19.14.4 RECENT DEVELOPMENTS 251
19.15 EUROFINS SCIENTIFIC 252
19.15.1 COMPANY SNAPSHOT 252
19.15.2 REVENUE ANALYSIS 252
19.15.3 PRODUCT PORTFOLIO 253
19.15.4 RECENT DEVELOPMENT 253
19.16 GUARDANT HEALTH 254
19.16.1 COMPANY SNAPSHOT 254
19.16.2 REVENUE ANALYSIS 254
19.16.3 PRODUCT PORTFOLIO 255
19.16.4 RECENT DEVELOPMENTS 255
19.17 HOLOGIC, INC. 256
19.17.1 COMPANY SNAPSHOT 256
19.17.2 REVENUE ANALYSIS 256
19.17.3 PRODUCT PORTFOLIO 257
19.17.4 RECENT DEVELOPMENT 257
19.18 MILAB SCIENTIFIC. 258
19.18.1 COMPANY SNAPSHOT 258
19.18.2 PRODUCT PORTFOLIO 258
19.18.3 RECENT DEVELOPMENT 258
19.19 NEOGENOMICS LABORATORIES 259
19.19.1 COMPANY SNAPSHOT 259
19.19.2 REVENUE ANALYSIS 259
19.19.3 PRODUCT PORTFOLIO 260
19.19.4 RECENT DEVELOPMENTS 260
19.20 OPKO HEALTH, INC. 261
19.20.1 COMPANY SNAPSHOT 261
19.20.2 REVENUE ANALYSIS 261
19.20.3 PRODUCT PORTFOLIO 262
19.20.4 RECENT DEVELOPMENT 262
19.21 QIAGEN 263
19.21.1 COMPANY SNAPSHOT 263
19.21.2 REVENUE ANALYSIS 263
19.21.3 PRODUCT PORTFOLIO 264
19.21.4 RECENT DEVELOPMENTS 264
19.22 QUEST DIAGNOSTICS INCORPORATED. 265
19.22.1 COMPANY SNAPSHOT 265
19.22.2 REVENUE ANALYSIS 265
19.22.3 PRODUCT PORTFOLIO 266
19.22.4 RECENT DEVELOPMENTS 266
19.23 SEEGENE INC 267
19.23.1 COMPANY SNAPSHOT 267
19.23.2 REVENUE ANALYSIS 267
19.23.3 PRODUCT PORTFOLIO 268
19.23.4 RECENT DEVELOPMENT 268
19.24 SIEMENS HEALTHCARE GMBH 269
19.24.1 COMPANY SNAPSHOT 269
19.24.2 REVENUE ANALYSIS 269
19.24.3 PRODUCT PORTFOLIO 270
19.24.4 RECENT DEVELOPMENT 270
20 QUESTIONNAIRE 271
21 RELATED REPORTS 275
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security